Amazon is not a health care company. It does not treat patients, sell insurance, or make prescription drugs. And although it has revolutionized modern commerce, it has not discovered a cure for cancer.

And yet, when the company announced a partnership with JPMorgan and Berkshire Hathaway to fix health care for employees last Tuesday, a $3.5 trillion industry began to tremble. Leading health stocks nosedived, losing $69 billion in value before the ink was dry on a 400-word press release that provided no detail on what Amazon will do in health care, or how it will do it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy